Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 6/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277774 | 1.00 | RORC (0.55) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL10277776 | 1.00 | RORC (0.55) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL3080127 | 0.90 | SIGMAR1 (0.51) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL7888069 | 0.88 | RORC (0.57) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL14498495 | 0.88 | RORC (0.57) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL5110560 | 0.88 | RORC (0.57) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL4661703 | 0.88 | RORC (0.57) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL4661705 | 0.88 | RORC (0.57) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL23417389 | 0.88 | F10 (0.54) | RORCF10PRSS1SLC6A4SLC6A3 | |
| SCHEMBL21413473 | 0.88 | F10 (0.54) | RORCF10PRSS1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| EP-2590942-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| WO-2012006202-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | RORC 1011/4885F10 1344/4885PRSS1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.